

**Results Announcement for Q2 2017**  
(unaudited figures S\$'000)

	<b>Q2 2017 (S\$'000)</b>	<b>Q2 2016 (S\$'000)</b>	<b>% change</b>
<b>Revenue</b>	120,088	118,953	1.0
<b>EBITDA</b>	23,254	23,592	(1.4)
<b>Operating Profit</b>	19,578	19,953	(1.9)
<b>Profit After Tax</b>	16,247	16,131	0.7
<b>PATMI</b>	16,763	16,672	0.5
<b>Diluted Earnings per Share (cts)</b>	0.95	0.95	-
<b>Net Assets Value per Share (cts)</b>	39.53	38.12 *	3.7

\* As at 31 December 2016

## Highlights of Q2 2017 Performance

- Record quarterly revenue of **S\$120.1 million**
- Profit After Tax and Minority Interests (**PATMI**) increased to **S\$16.8 million**
- Healthy cash position of **S\$112.4 million**
- **Interim Dividend** of **0.5 cents** payable on 31 August 2017

## ***RafflesMedicalGroup* Maintains Growth Amidst Challenging Business Conditions**

Singapore, 31 July 2017 – *RafflesMedicalGroup* (the **Group**), a leading integrated healthcare organisation in Asia, announced a record quarterly revenue of **S\$120.1** million in Q2 2017, a **1.0%** increase from **S\$119.0** million in Q2 2016.

Despite the softer than expected demand from foreign patients, the Group continues to register growth in patient load. Hospital Services division recorded a revenue increase of **0.3%** while the revenue of Healthcare Services division decreased marginally by **1.1%**.

Net profit after tax attributable to owners of the Company increased by **0.5%** from **S\$16.7** million in Q2 2016 to **S\$16.8** million in Q2 2017. Revenue growth was offset by higher staff costs as well as consumables used. The increase in staff costs was due to the recruitment of more specialists, management and clinical staff in view of the opening of *RafflesHospital Extension* in the last quarter of this year.

The Group continued to generate strong operating cashflows from its business units. After accounting for distribution of final dividend of **S\$5.5** million and payment of **S\$53.6** million for investment properties under development, it has a healthy cash position of **S\$112.4** million as at 30 June 2017.

The Directors announced an interim dividend of **0.5 Singapore cents** per ordinary share for the financial year ending 31 December 2017. The dividend will be paid on 31 August 2017.

*RafflesMedical* continued to expand its network of clinics by opening a new clinic at Hillion Mall in Q2 2017. At the same time, existing clinics at Asia Square, Clementi and Nex were relocated or refurbished to serve our patients better. Four new clinics are scheduled to open in Q3 2017, two at the new Changi Airport Terminal 4 and two in-house clinics in Dover and Tampines. Northpoint City clinic will re-open in September 2017 after the mall refurbishment. These initiatives will offer better service and greater convenience to our patients.

In Q2 2017, **RafflesMedical** continued to acquire new clients for the Group in the property, shipping, commodity, hospitality, education, childcare, finance, services and government sectors.

**RafflesHospital's** Emergency Care Collaboration with the Ministry of Health (MOH) was extended in June 2017 for another five years. Under the collaboration, SCDF ambulances bring patients to **RafflesHospital** for subsidised care. In addition, to build up the breadth and depth of the hospital's capabilities, **RafflesHospital** recruited new specialists in paediatrics and medical oncology.

The new **RafflesHospital Extension** will open in Q4 2017. It will allow the hospital to further increase its breadth and depth of clinical services with expanded capacity in both specialist outpatient and inpatient facilities.

Construction of the 700-bed **RafflesHospital Chongqing** and 400-bed **RafflesHospital Shanghai** is progressing well. These hospitals are targeted to be operational by second half 2018 and second half 2019 respectively.

**Raffles Holland V**, representing the Group's initiative of locating comprehensive healthcare services with other lifestyle attractions in prime suburban regions, is fully leased as at 31 July 2017.

Says Dr Loo Choon Yong, Executive Chairman of **RafflesMedicalGroup**: "This is a rather challenging period for companies in Singapore. The opening of **RafflesHospital Extension** as well as that of the Raffles hospitals in Chongqing and Shanghai will continue to provide growth opportunities for the Group."

\*\*\*\*\*

For media queries, please contact:

Magdalene Lee (Ms)

Senior Manager, Corporate Communications

Raffles Medical Group

Tel: 6311 1318 Mobile: 9673 7403

Email: [lee\\_magdalene@rafflesmedical.com](mailto:lee_magdalene@rafflesmedical.com)

## About Us

**RafflesMedicalGroup (SGX: BSL)** is a leading integrated private healthcare provider in the region, providing comprehensive services from primary to tertiary care.

**RafflesMedical** clinics form one of the largest networks of private family medicine centres in Singapore.

**RafflesHospital**, the flagship of Raffles Medical Group, is a private tertiary hospital located in the heart of Singapore offering a wide range of specialist medical and diagnostic services for both inpatients and outpatients. Representing more than 30 disciplines, our team of specialists constitutes a group practice combining sub-specialty expertise and teamwork to ensure optimal, affordable and high quality care for our patients. The Group also has representative offices and patient liaison offices in Indonesia, Vietnam, Cambodia, Brunei, Bangladesh and the Russian Far East, as well as associates throughout the Asia-Pacific region.

**RafflesMedical International** operates medical facilities beyond Singapore in 12 cities across China, Japan, Vietnam and Cambodia.

**RafflesDental** is a team-based multispecialty dental group in Singapore and China.

**RafflesHealthinsurance** provides healthcare insurance to corporate and individual clients.

For more information, please refer to our website at [www.rafflesmedicalgroup.com](http://www.rafflesmedicalgroup.com).